3 results
The aim of the trial is to obtain data on the optimal dose, feasibility and pharmacokinetics of bumetanide when given as an add-on treatment for seizures in full term babies with hypoxic ischemic encephalopathy (HIE). Bumetanide will be given in a…
Primary Objectives:• To assess the efficacy (progression-free survival [PFS]) of DCC-2618 by independent radiologic review in patients with advanced gastrointestinal stromal tumors (GIST) who have previously received first-line therapy with…
Primary Objective:Assess the antitumor activity of BDTX-189 as a single agent by evaluation of objective response as determined by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in patients with allosteric human epidermal growth…